Intellia Therapeutics (NTLA) PT Lowered to $80 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts NTLA Hot Sheet
Price: $13.23 -0.68%
Rating Summary:
22 Buy, 9 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Rating Summary:
22 Buy, 9 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
Stifel analyst Dae Gon Ha lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $80.00 (from $93.00) while maintaining a Buy rating.
You May Also Be Interested In
- Exlservice (EXLS) PT Raised to $48 at Stifel
- Ligand Pharma (LGND) PT Raised to $350 at Stifel
- Establishment Labs Inc. (ESTA) PT Lowered to $93 at BTIG
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
